News

Call for Judges for Science Fair and BioGENEius Challenge

Each year, Virginia Bio recruits volunteer judges from the membership to attend the Virginia State Science and Engineering Fair to select the top three winners in the field of biosciences. The time commitment is limited to a pre-event online review of the submissions to select the finalists and then a few hours onsite at the Fair to interview and select the final winners. Lunch is provided to all judges by the Fair. The process is extremely easy and, by all accounts, very rewarding. This years Fair is in Roanoke on April 18.

Volunteer judges are also needed for the Virginia BioGENEius Challenge. Students submit their projects in either the categories of biotechnology, agriculture or industrial/ environmental science. The judging for the challenge is done virtually. Judges will be sent applicant information, abstracts and posters by April 25, and results will be due back to Virginia Bio on May 1. Winners from the state challenge will go on to compete in the U.S. National BioGENEius Challenge taking place during the BIO International Conference in San Diego, CA in June.

 

Please contact Caron Trumbo if interested in volunteering your time!

Recent News

06/11/2026

Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing

Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that it has acquired Azora Therapeutics, Inc. (“Azora”), a biopharmaceutical company developing treatments for serious inflammatory diseases. The acquisition brings Azora’s lead asset AT177, a proprietary colon‑targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure, into Adial’s pipeline.

06/11/2026

Luna Labs Launches 3 Waves Venture Spinout to Commercialize Advanced Vestibular Stimulation Technology

Luna Labs today announced the launch of 3 Waves, Inc. (“3Waves”), a dual-use spinout company that was established to commercialize advanced virtual and mixed reality technologies for defense, commercial simulation, and medical applications. As part of the spinout, 3Waves and Mayo Clinic executed an exclusive license to support the development of next-generation vestibular stimulation systems

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and